NGLY1 deficiency: a prospective natural history study

Sandra Tong, Pamela Ventola, Christina H Frater, Jenna Klotz, Jennifer M Phillips, Srikanth Muppidi, Selina S Dwight, William F Mueller, Brendan J Beahm, Matt Wilsey, Kevin J Lee, Sandra Tong, Pamela Ventola, Christina H Frater, Jenna Klotz, Jennifer M Phillips, Srikanth Muppidi, Selina S Dwight, William F Mueller, Brendan J Beahm, Matt Wilsey, Kevin J Lee

Abstract

N-glycanase 1 (NGLY1) deficiency is a debilitating, ultra-rare autosomal recessive disorder caused by loss of function of NGLY1, a cytosolic enzyme that deglycosylates other proteins. It is characterized by severe global developmental delay and/or intellectual disability, hyperkinetic movement disorder, transient elevation of transaminases, (hypo)alacrima and progressive, diffuse, length-dependent sensorimotor polyneuropathy. A prospective natural history study (NHS) was conducted to elucidate clinical features and disease course. Twenty-nine participants were enrolled (15 onsite, 14 remotely) and followed for up to 32 months, representing ~29% of the ~100 patients identified worldwide. Participants exhibited profound developmental delays, with almost all developmental quotients below 20 on the Mullen Scales of Early Learning, well below the normative score of 100. Increased difficulties with sitting and standing suggested decline in motor function over time. Most patients presented with (hypo)alacrima and reduced sweat response. Pediatric quality of life was poor except for emotional function. Language/communication and motor skill problems including hand use were reported by caregivers as the most bothersome symptoms. Levels of the substrate biomarker, GlcNAc-Asn (aspartylglucosamine; GNA), were consistently elevated in all participants over time, independent of age. Liver enzymes were elevated for some participants but improved especially in younger patients and did not reach levels indicating severe liver disease. Three participants died during the study period. Data from this NHS informs selection of endpoints and assessments for future clinical trials for NGLY1 deficiency interventions. Potential endpoints include GNA biomarker levels, neurocognitive assessments, autonomic and motor function (particularly hand use), (hypo)alacrima and quality of life.

© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Figures

Figure 1
Figure 1
NGLY1 deficiency clinical features and summary of study protocol. Core clinical features of NGLY1 deficiency (1–3) are shown above. The study protocol is summarized below.
Figure 2
Figure 2
Scatter plot of Mullen-DQ vs chronological age. Individual participant DQ scores over time are shown. The normative value is 100 ± 15. Black symbols are female and gray symbols are male subjects.
Figure 3
Figure 3
Vineland ABC. Individual participant Vineland ABC scores over time are shown. The normative value is 100 ± 15 (shaded area). Black symbols are female and gray symbols are male subjects.
Figure 4
Figure 4
PDMS-2 gross motor (A) and fine motor (B) function. Individual participant PDMS-2 gross motor (A) and fine motor (B) function scores over time are shown. The normative values are 100 ±15. Black symbols are female and gray symbols are male subjects.
Figure 5
Figure 5
Motor function: Standing ability. Individual participant standing ability over time is shown. Black symbols are female and gray symbols are male subjects.
Figure 6
Figure 6
Schirmer’s lacrimation test. Results from left eye. Wetting of ≤5 mm per 5 min is considered a strong positive test for (hypo)alacrima (17). Greater than 10 mm is considered normal (gray line).
Figure 7
Figure 7
PedsQL (total score) vs. visit. Black symbols are female and gray symbols are male subjects.
Figure 8
Figure 8
Plasma GNA concentration vs. age at collection for participants as measured over time. Age at sample collection and GNA concentration were compared to determine whether there was a significant relationship. The line is the trend line with statistical correlation shown. Each point represents a measurement, and points connected by short black lines are consecutive measurements for the same participant.
Figure 9
Figure 9
ALT (units per liter [U/L]) vs. chronological age. Legend: If participants had multiple laboratory measurements at the same visit, the highest value was selected for analysis.
Figure 10
Figure 10
AST (U/L) vs chronological age. Legend: If participants had multiple laboratory measurements at the same visit, the highest value was selected for analysis.

References

    1. Adams, J. and Schaaf, C.P. (2018) Diagnosis and genetics of alacrima. Clin. Genet., 94, 54–60.
    1. Enns, G.M., Shashi, V., Bainbridge, M., Gambello, M.J., Zahir, F.R., Bast, T., Crimian, R., Schoch, K., Platt, J., Cox, R. et al. (2014) Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway. Genet Med., 16, 751–758.
    1. Lam, C., Wolfe, L., Need, A., Shashi, V. and Enns, G. (2018) NGLY1-related congenital disorder of deglycosylation. In: Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (ed.) GeneReviews® [Internet]. University of Washington, Seattle, WA, USA, 1993–2023. .
    1. Pandey, A., Adams, J.M., Han, S.Y. and Jafar-Nejad, H. (2022) NGLY1 deficiency, a congenital disorder of deglycosylation: from disease gene function to pathophysiology. Cell, 11, 1155.
    1. Dabaj, I., Sudrié-Arnaud, B., Lecoquierre, F., Raymond, K., Ducatez, F., Guerrot, A.-M., Snanoudj, S., Coutant, S., Sauger-Veber, P., Marret, S. et al. (2021) NGLY1 deficiency: a rare newly described condition with a typical presentation. Life., 11, 187.
    1. Kalfon, L., Baydany, M., Samra, N., Heno, N., Segal, Z., Eran, A., Yulevich, A., Fellig, Y., Mandel, H. and Falik-Zaccai, T.C. (2022) Congenital hypotonia: cracking a SAGA of consanguineous kindred harboring four genetic variants. Mol. Genet. Genomic Med., 10, e1849.
    1. Stuut, T., Popescu, O. and Oviedo, A. (2021) N-Glycanase 1 deficiency is a rare cause of pediatric neurodegeneration with neuronal inclusions and liver steatosis. Cureus, 13, e19126.
    1. Suzuki, T., Huang, C. and Fujihira, H. (2016) The cytoplasmic peptide: N-glycanase (NGLY1) – structure, expression and cellular functions. Gene, 577, 1–7.
    1. Haijes, H.A., de Sain-van der Velden, M.G.M., Prinsen, H.C.M.T., Willems, A.P., van der Ham, M., Gerrits, J., Couse, M.H., Friedman, J.M., van Karnebeek, C.D.M., Selby, K.A. et al. (2019) Aspartylglycosamine is a biomarker for NGLY1-CDDG, a congenital disorder of deglycosylation. Mol. Genet. Metab., 127, 368–372.
    1. Mueller, W.F., Zhu, L., Tan, B., Dwight, S., Beahm, B., Wilsey, M., Wechsler, T., Mak, J., Cowan, T., Pritchett, J. et al. (2022) GlcNAc-Asn is a biomarker for NGLY1 deficiency. J. Biochem., 171, 177–186.
    1. Zhu, L., Tan, B., Dwight, S., Beahm, B., Wilsey, M., Crawford, B.E., Schweighardt, B., Cook, J.W., Wechsler, T. and Mueller, W.F. (2022) AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 deficiency. Meth. Clin. Dev., 27, 269–271.
    1. Lam, C., Ferreira, C., Krasnewich, D., Toro, C., Latham, L., Zein, W.M., Lehky, T., Brewer, C., Baker, E.H., Thurm, A. et al. (2017) Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. Genet. Med., 19, 160–168.
    1. Cahan, E.M. and Frick, S.L. (2019) Orthopaedic phenotyping of NGLY1 deficiency using an international, family-led disease registry. Orphanet. J. Rare. Dis., 14, 148.
    1. Need, A.C., Shashi, V., Hitomi, Y., Schoch, K., Shianna, K.V., McDonald, M.T., Meisler, M.H. and Goldstein, D.B. (2012) Clinical application of exome sequencing in undiagnosed genetic conditions. J. Med. Genet., 49, 353–361.
    1. Levy, R.J., Frater, C.H., Gallentine, W.B., Phillips, J.M. and Ruzhnikov, M.R. (2022) Delineating the epilepsy phenotype of NGLY1 deficiency. J. Inherit. Metab. Dis., 45, 571–583.
    1. Karampatakis, V., Karamitsos, A., Skriapa, A. and Pastiadis, G. (2010) Comparison between normal values of 2- and 5-minute Schirmer test without anesthesia. Cornea, 29, 497–501.
    1. Li, N., Deng, X.G. and He, M.F. (2012) Comparison of the Schirmer I test with and without topical anesthesia for diagnosing dry eye. Int. J. Ophthalmol., 5, 478–481.
    1. Ryan, C.S., Conlee, E.M., Sharma, R., Sorenson, E.J., Boon, A.J. and Laughlin, R.S. (2019) Nerve conduction normal values for electrodiagnosis in pediatric patients. Muscle Nerve, 60, 155–160.
    1. Illigens, B.M.W. and Gibbons, C.H. (2009) Sweat testing to evaluate autonomic function. Clin. Auton. Res., 19, 79–87.
    1. Novak, P. (2011) Quantitative autonomic testing. J. Vis. Exp., 53, 2502.
    1. Hullmann, S.E., Ryan, J.L., Ramsey, R.R., Chaney, J.M. and Mullins, L.L. (2011) Measures of general pediatric quality of life. Arthritis Care Res., 63, S420–S430.
    1. Valier, A.R.S., Bacon, C.E.W., Bay, R.C., Molzen, E., Lam, K.C. and Valovich McLeod, T.C. (2017) Reference values for the pediatric quality of life scale inventory and the multidimensional fatigue scale in adolescent athletes by sport and sex. Am. J. Sports Med., 45, 2723–2729.
    1. Pinto, P.L., Machado, C., Janiero, P., Dupont, J., Quintas, S., Sousa, A.B. and Gaspar, A. (2020) NGLY1 deficiency – a rare congenital disorder of glycosylation. J. Inherit. Metab. Dis. Rep., 53, 2–9.
    1. Willems, M., Wells, C.F., Coubes, C., Pequignot, M., Kouny, A. and Michon, F. (2022) Hypoalacrima and alacrima as diagnostic features for genetic or congenital conditions. Invest. Ophthalmol. Vis. Sci., 63, 3.
    1. Hall, P.L., Lam, C., Alexander, J.J., Asif, G., Berry, G.T., Ferreira, C., Freeze, H.H., Gahl, W.A., Nickander, K.K., Sharer, J.D. et al. (2018) Urine oligosaccharide screening by MALDI-TOF for the identification of NGLY1 deficiency. Mol. Genet. Metab., 124, 82–86.
    1. Chang, C.A., Wei, X.C., Martin, S.R., Sinasac, D.S. and Al-Hertani, W. (2019) Transiently elevated plasma methionine, S-adenosylmethionine and S-adenosylhomocysteine: unreported laboratory findings in a patient with NGLY1 deficiency, a congenital disorder of deglycosylation. JIMD. Rep., 49, 21–29.
    1. Heeley, J. and Shinawi, M. (2015) Multi-systemic involvement in NGLY1-related disorder caused by two novel mutations. Am. J. Med. Genet. A, 167A, 816–820.
    1. Lipiński, P., Cielecka-Kuszyk, J., Socha, P. and Tylki-Szymanska, A. (2020) Liver involvement in NGLY1 congenital disorder of deglycosylation. Pol. J. Pathol., 71, 66–68.
    1. Rios-Flores, I.M., Bonal-Perez, M.A., Castellanos-Gonzalez, A., Velez-Gomez, E., Bertoli-Avella, A.M., Bobadilla-Morales, L., Pena-Padilla, C., Appendini-Andrade, V., Corona-Rivera, A., Romero-Valenzuela, I. et al. (2020) Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation. Eur. J. Med. Genet., 63, 103952.
    1. Lipari Pinto, P., Machado, C., Janeiro, P., Dupont, J., Quintas, S., Sousa, A.B. and Gaspar, A. (2020) NGLY1 deficiency—a rare congenital disorder of deglycosylation. J. Inherit. Metab. Dis. Rep., 53, 2–9.
    1. Aylward, G.P. and Stanchin, T. (2008) Chapter 7: Screening and assessment tools. In Wolraich, M.L. (ed), Developmental-Behavioral Pediatrics. Mosby Elsevier, Philadelphia, PA, pp. 123–201.
    1. Farmer, C., Adedipe, D., Bal, V., Chlebowski, C. and Thurm, A. (2020) Concordance of the Vineland adaptive behaviour scales, second and third editions. J. Intellect. Disabil. Res., 64, 18–26.
    1. Rebelo, M., Serrano, J., Duarte-Mendes, P., Monteiro, D., Paulo, R. and Marinho, D.A. (2021) Evaluation of the psychometric properties of the Portuguese Peabody developmental motor Scales-2 edition: a study with children aged 12 to 48 months. Children (Basel), 8, 1049.
    1. Spencer, T.D. and Kruse, L. (2010) Beery-Buktenica Developmental Test of Visual Motor Integration. In Volkmar, F.R. (ed), Encyclopedia of Autism Spectrum Disorders. Springer, New York, NY.
    1. Pereira, A.C., Ribeiro, M.C. and Araujo, A.P.Q.C. (2016) Timed motor function tests capacity in healthy children. Arch. Dis. Child., 101, 147–151.
    1. de Baptista, C.R.J.A., Vicente, A.M., Souza, M.A., Cardoso, J., Ramalho, V.M. and Mattiello-Sverzut, A.C. (2020) Methods of 10-meter walk test and repercussions for reliability obtained in typically developing children. Rehabil. Res. Pract., 2020, 1–7.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir